Starpharma Holdings 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Cheryl Maley

최고 경영자

AU$475.8k

총 보상

CEO 급여 비율	51.3%
CEO 임기	less than a year
CEO 소유권	0.03%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	2.9yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Cheryl Maley 의 보수는 Starpharma Holdings 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	AU$476k	AU$244k	-AU$8m

보상 대 시장: Cheryl 의 총 보상 ($USD 311.92K )은 Australian 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 299.68K ).

보상과 수익: Cheryl 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Cheryl Maley (55 yo)

less than a year

테뉴어

AU$475,764

보상

Mrs. Cheryl Maley, B.Sc, DipEd, MBA, GAICD, serves as Chief Executive Officer, Managing Director and Director of Starpharma Holdings Limited since January 8. 2024. She served as Non-Executive Director of C...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Cheryl Maley	CEO, MD & Director	less than a year	AU$475.76k	0.030% A$ 12.3k
Robert Thomas	Non-Executive Chairman	10.9yrs	AU$136.95k	0.66% A$ 269.5k
David McIntyre	Non-Executive Director	4.7yrs	AU$81.00k	0.10% A$ 41.4k
Jeff Davies	Non-Executive Director	2.6yrs	AU$75.00k	0.22% A$ 91.1k
Russell Basser	Non-Executive Director	1.8yrs	AU$77.04k	0.065% A$ 26.6k
Lynda Cheng	Independent Non-Executive Director	3.3yrs	AU$88.54k	0.041% A$ 16.7k

2.9yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 이사회: SPL 의 이사회는 경험(평균 재직 기간 2.9 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Starpharma Holdings 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Starpharma Holdings Limited, Annual General Meeting, Nov 26, 2024

Non-Executive Director recently bought AU$80k worth of stock

Starpharma Holdings Limited Appoints Cheryl Maley as Chief Executive Officer, Effective 8 January 2024

Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2023

No independent directors

Starpharma Holdings Limited Announces Change of Company Secretary

Recent updates

Starpharma Holdings Limited, Annual General Meeting, Nov 26, 2024

Full year 2024 earnings released: AU$0.02 loss per share (vs AU$0.038 loss in FY 2023)

Non-Executive Director recently bought AU$80k worth of stock

First half 2024 earnings released: AU$0.003 loss per share (vs AU$0.02 loss in 1H 2023)

Starpharma Holdings Limited Appoints Cheryl Maley as Chief Executive Officer, Effective 8 January 2024

Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2023

Starpharma Holdings Limited Announces Viraleze for Respiratory and Cold Viruses

No independent directors

Starpharma Holdings Limited Announces Change of Company Secretary

Full year 2023 earnings released: AU$0.038 loss per share (vs AU$0.04 loss in FY 2022)

New minor risk - Share price stability

Starpharma Announces Resignation of Jackie Fairley as Chief Executive Officer

New minor risk - Market cap size

First half 2023 earnings released: AU$0.02 loss per share (vs AU$0.021 loss in 1H 2022)

Starpharma Holdings Limited Announces Board Changes

Starpharma Holdings Limited Appoints Russell Basser as Non-Executive Director, Effective from 20 February 2023

Starpharma Holdings Limited Announces Resignation of Nigel Baade as Company Secretary

Starpharma Achieves Marketing Authorization of the Nasal Spray Product, VIRALEZETM, in Indonesia

Starpharma Holdings Limited Announces Positive AZD0466 Clinical Data Presented by Astrazeneca

Starpharma Holdings Limited Announces Management Changes

Starpharma Holdings Limited Launches VIRALEZE in Hong Kong and Macau

Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2022

Starpharma Holdings Limited Presents Compelling Data in Prostate Cancer At ESMO

Starpharma Holdings Limited Announces New Clinical Data for Dep Cabazitaxel in Prostate Cancer

Full year 2022 earnings released: AU$0.04 loss per share (vs AU$0.05 loss in FY 2021)

Starpharma Announces VIRALEZE Protects Against Omicron in Viral Challenge Model

Starpharma Announces SPL7013, the Antiviral Agent in VIRALEZETM Nasal Spray

Starpharma Holdings Limited Appoints Jeff Davies as Director

Starpharma Holdings Limited Announces Relaunch of VIRALEZETM in UK

Starpharma Announces SPL7013 in Viraleze Virucidal Against Omicron

Starpharma Holdings Limited Appoints Jeff Davies as Non-Executive Director, Effective 1 April 2022

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Starpharma Holdings Limited Announces Positive Interim Results from Its Ongoing Phase 2 Trial of DEP® Cabazitaxel

Starpharma Announces US Patent and Trademark Office Has Granted New Patent in Relation to DEP® Cabazitaxel

Independent Non-Executive Director recently bought AU$71k worth of stock

Full year 2021 earnings released: AU$0.05 loss per share (vs AU$0.039 loss in FY 2020)

Starpharma Holdings Limited Announces Publication of New Data Demonstrating the Protective Efficacy of VIRALEZETM Antiviral Nasal Spray against SARS-CoV-2 Challenge in Vivo

Independent Non-Executive Deputy Chairman Peter Turvey has left the company

Starpharma Releases New Data About SPL7013

Starpharma Holdings Limited's VIRALEZE Antiviral Nasal Spray Registered for Sale in India

Starpharma Holdings Limited Announces VIRALEZE SPL7013 Highly Active in UK Variant of Coronavirus

Starpharma Announces DEP HER2-Lutetium Outperforms in Human Breast Cancer Model

Starpharma Signs DEP ADC Research Agreement with MSD

Starpharma Holdings Limited Announces AZD0466 Clinical DEP Program Global Expansion

New 90-day high: AU$1.79

New 90-day high: AU$1.66

New 90-day low: AU$1.27

Starpharma Holdings Limited Announces Board Changes

Starpharma Holdings Limited Announces SPL7013 Shows Potent Antiviral Activity in RSV Expanding Use for Nasal Spray

Starpharma Holdings Limited announced that it has received AUD 45 million in funding

Starpharma Holdings Limited announced that it expects to receive AUD 45 million in funding

Starpharma Holdings Limited Announces That Australia Therapeutic Goods Administration Approves Expansion of the Marketing Authorisation for Vivagel® Bv

New 90-day high - AU$1.73

Earnings released

New 90-day high - AU$1.28

CEO 보상 분석

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령